# SDC Figure 1 (updated). Association between cumulative tenofovir exposure and risk of CKD in subgroups defined by baseline characteristics (*excluding those with CKD at baseline*)*

Characteristic	Events (n)	Participants (n)		Hazard Ratio (95% CI)	Interaction P Value
Age <46 years	163	5262		1.63 (1.40, 1.89)	**0.043**
Age ≥46 years	370	4900		1.31 (1.14, 1.52)	
Black	245	4998		1.26 (1.08, 1.47)	0.13
Non-black	288	5164		1.48 (1.29, 1.71)	
No Proteinuria	365	8261		1.45 (1.26, 1.66)	0.27
Proteinuria	168	1901		1.27 (1.05, 1.53)	
No Smoking	464	8267		1.41 (1.24, 1.60)	0.64
Smoking	69	1895		1.30 (0.95, 1.77)	
No CVD	460	9427		1.47 (1.30, 1.67)	**0.016**
CVD	73	735		0.85 (0.56, 1.31)	
No Dyslipidemia	428	8731		1.47 (1.29, 1.68)	0.071
Dyslipidemia	105	1431		1.15 (0.90, 1.45)	
No Diabetes	449	9475		1.47 (1.29, 1.68)	**0.041**
Diabetes	84	687		1.03 (0.75, 1.41)	
No Hypertension	178	6417		1.63 (1.37, 1.93)	**0.018**
Hypertension	355	3745		1.28 (1.15, 1.42)	
No Drug Abuse	391	6417		1.42 (1.24, 1.61)	0.50
Drug Abuse	142	3745		1.29 (1.02, 1.64)	
Viral Load <100,000copies/mL	347	6823		1.43 (1.24-1.64)	0.37
Viral Load >100,000copies/mL	186	3339		1.29 (1.09-1.53)	
CD4 Count 0-199 cells/mm^3	267	4473		1.33 (1.11-1.61)	0.28
CD4 Count 200-350 cells/mm^3	115	2131		1.53 (1.16-2.01)	
CD4 Count >350 cells/mm^3	151	3558		1.36 (1.08-1.72)	
BMI <25 kg/m^2	285	5391		1.25 (1.05-1.50)	0.64
BMI 25-30 kg/m^2	174	3153		1.70 (1.38-2.11)	
BMI >30 kg/m^2	66	1215		1.39 (0.98-1.97)	

0.5   1   2   4

*CV risk category based on Framingham risk score (<10% = low, 10-20% = moderate, >20% = high). All estimates based on multivariable adjusted Cox models described in Table 2. P value for test of interaction between cumulative tenofovir use and characteristic reported. Abbreviations: CI (confidence interval), eGFR (estimated glomerular filtration rate), CVD (cardiovascular disease), BMI (body mass index).